- Home
- APAM vs SLNO Comparison
APAM vs SLNO Comparison
Compare APAM & SLNO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | APAM | SLNO |
|---|---|---|
| Founded | 1994 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.6B | 2.3B |
| IPO Year | 2011 | 2014 |
Fundamental Metrics
Financial Performance| Metric | APAM | SLNO |
|---|---|---|
| Price | $37.55 | $52.86 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 5 | 9 |
| Target Price | $43.00 | ★ $83.00 |
| AVG Volume (30 Days) | 719.9K | ★ 6.1M |
| Earning Date | 04-28-2026 | 05-08-2026 |
| Dividend Yield | ★ 10.81% | N/A |
| EPS Growth | 10.66 | ★ 108.90 |
| EPS | ★ 4.05 | 0.39 |
| Revenue | ★ $1,196,688,000.00 | $1,450,788.00 |
| Revenue This Year | $5.96 | $150.46 |
| Revenue Next Year | $5.05 | $50.37 |
| P/E Ratio | ★ $9.25 | $135.49 |
| Revenue Growth | 7.63 | ★ 138.82 |
| 52 Week Low | $34.99 | $29.43 |
| 52 Week High | $48.46 | $89.12 |
Technical Indicators
Market Signals| Indicator | APAM | SLNO |
|---|---|---|
| Relative Strength Index (RSI) | 50.60 | 77.04 |
| Support Level | $35.01 | $48.91 |
| Resistance Level | $38.75 | $55.47 |
| Average True Range (ATR) | 1.04 | 0.11 |
| MACD | 0.04 | -0.45 |
| Stochastic Oscillator | 58.10 | 92.86 |
Price Performance
Historical ComparisonAbout APAM Artisan Partners Asset Management Inc.
Artisan Partners Asset Management Inc is a investment management firm providing a range of investment strategies to a diverse group of clients around the world. Each of the company's strategies is managed by one of its several investment teams. Investment management services are offered to institutions through separate accounts and mutual funds. Artisan's investment offerings include several long-only, equity investment strategies across a multitude of market capitalization segments and investing styles in both the United States and international markets. The company operates as one segment in the investment management business. The company generates maximum portion of its revenues from clients domiciled in countries outside the United States.
About SLNO Soleno Therapeutics Inc.
Soleno Therapeutics Inc is a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases. Its product candidate DCCR (Diazoxide Choline) Extended-Release tablets, is a proprietary extended-release formulation of a crystalline salt of diazoxide. DCCR has demonstrated the ability to activate the KATP channel in the brain, pancreas, and fat tissue.